Skip to main content
TipRanks
Go Ultimate75% OFF

euglena Co., Ltd. (2931) AI Stock Analysis

1 Followers
JP:2931

euglena Co., Ltd.

(TSE/TYO:2931)

Select Model
Rating:48Neutral
Price Target:JPY 300.00â–¼(-7.12% Downside)
Action:reiterated
Date:11/08/26

The score is driven primarily by improving financial performance (notably stronger operating results and cash flow in 2024–2025), but is held back by continued net losses and negative ROE. Technicals are notably weak with the price below key moving averages and bearish momentum indicators, while valuation is constrained by a negative P/E and a low dividend yield.

Positive Factors
Revenue and Operating RecoverySustained revenue expansion alongside a move into operating profitability indicates improving scale and execution. If maintained, this combination can strengthen the company’s ability to fund product development, support distribution growth, and convert its microalgae platform into a more durable earnings base.
Negative Factors
Net Losses and Negative ROEOperating improvement has not yet translated into sustained bottom-line profitability or positive shareholder returns. Continued net losses can constrain internally generated capital, weaken return potential, and leave the company more dependent on further operating gains to establish a durable earnings model.

euglena Co., Ltd. (2931) vs. iShares MSCI Japan ETF (EWJ)

-30%-20%-10%0%10%20%30%JP:2931-23.28%EWJ+16.02%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 43.80B
Dividend Yield
0.62%
Average Volume (3M)
670.12K
Price to Earnings (P/E)
-256.3
Beta (1Y)
0.51
Revenue Growth
7.72%
EPS Growth
-1053.09%
Country
Japan
Employees
793
Sector
Consumer Defensive
Sector Strength
62
Industry
Household & Personal Products

euglena Co., Ltd. Business Overview & Revenue Model

Company Description

Euglena Co., Ltd. is a Japanese enterprise specializing in the research, development, cultivation, and marketing of microalgae. Its operations are structured around two primary divisions: Healthcare Business and Energy/Environment Business. The compa...

How the Company Makes Money

The company makes money primarily by selling microalgae-derived products and ingredients. Key revenue streams include: (1) Consumer product sales in the health/functional food domain, where Euglena-branded supplements, health foods, and related consu...

euglena Co., Ltd. Financial Statement Overview

Summary

Strong multi-year revenue expansion and a sharp operating recovery (operating profit turning positive in 2024 and improving in 2025) with consistently high gross margins. However, net income remains negative and returns on equity are still below zero, keeping the score moderate.

Income Statement

46Neutral

Balance Sheet

50Neutral

Cash Flow

63Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue52.32B50.37B47.62B46.48B44.39B27.54B
Gross Profit35.78B32.06B30.00B29.81B29.05B16.22B
EBITDA6.67B6.47B3.90B1.51B-359.00M-3.50B
Net Income-172.00M-805.00M-650.00M-2.65B-2.67B-4.03B
Balance Sheet
Total Assets69.27B72.33B73.26B59.62B57.27B61.01B
Cash, Cash Equivalents and Short-Term Investments17.17B21.16B20.63B15.79B9.95B10.19B
Total Debt23.06B27.68B25.92B25.07B22.22B24.91B
Total Liabilities37.70B43.80B41.14B39.40B37.92B40.42B
Stockholders Equity33.18B30.96B31.70B20.21B19.35B20.58B
Cash Flow
Free Cash Flow04.98B2.23B345.00M595.00M1.18B
Operating Cash Flow05.19B2.65B658.00M924.00M1.38B
Investing Cash Flow0-585.00M-7.99B-646.00M1.23B-10.34B
Financing Cash Flow0-2.43B-485.00M5.83B-2.99B12.06B

euglena Co., Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price323.00

Price Trends

50DMA335.04Negative
100DMA339.42Negative
200DMA362.59Negative

Market Momentum

MACD-5.82Negative
RSI48.20Neutral
STOCH42.71Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2931, the sentiment is Neutral. The current price of 323.00 is below the 20-day moving average (MA) of 323.65, below the 50-day MA of 335.04, and below the 200-day MA of 362.59, indicating a bearish trend. The MACD of -5.82 indicates Negative momentum. The RSI at 48.20 is Neutral, neither overbought nor oversold. The STOCH value of 42.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2931.

euglena Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

JP:2931 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4452JP:445273OutperformJPY 3.66T26.2012.88%1.92%6.31%18.40%
JP:4911JP:491168NeutralJPY 1.67T35.12―1.19%5.79%―
JP:4922JP:492267NeutralJPY 351.83B27.614.51%2.27%4.49%70.29%
JP:4527JP:452765NeutralJPY 599.90B17.6410.90%1.93%7.39%-7.02%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
JP:4967JP:496761NeutralJPY 524.70B114.702.19%1.48%2.46%-60.25%
JP:2931JP:293148NeutralJPY 45.06B-256.35―0.62%7.72%-1053.09%

* Consumer Defensive Sector Average

Performance Comparison

-25%0%25%50%75%JP:2931JP:4452JP:4967JP:4922JP:4527JP:4911Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:2931 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:2931euglena Co., Ltd.323.00-98.00-23.28%
JP:4452Kao Corp4046.00843.9526.36%
JP:4967Kobayashi Pharmaceutical Co 7075.001880.5836.20%
JP:4922Kose Corporation6167.001286.1126.35%
JP:4527Rohto Pharmaceutical Co 2584.00180.497.51%
JP:4911Shiseido Company,Limited4191.001884.7081.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026